Cargando…
Correction: Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial
Autores principales: | Radhakrishnan, Venkatraman, Bakhshi, Sameer, Kayal, Smita, Thampy, Cherian, Batra, Ankit, Shenoy, Praveen Kumar, Kumar, Hemanth, Rajaraman, Swaminathan, Chaudhary, Shilpi, Bisht, Reema, Dubashi, Biswajit, Ganesan, Trivadi S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515103/ https://www.ncbi.nlm.nih.gov/pubmed/36167799 http://dx.doi.org/10.1038/s41408-022-00735-0 |
Ejemplares similares
-
Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial
por: Radhakrishnan, Venkatraman, et al.
Publicado: (2022) -
Baricitinib: Two Birds with One Stone
por: Saj, Fen, et al.
Publicado: (2022) -
Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome
por: Radhakrishnan, Venkatraman, et al.
Publicado: (2016) -
Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India
por: Murali, Aditya Navile, et al.
Publicado: (2017) -
Poster: ABCL-334: Impact of COVID-19 Pandemic on Treatment Duration in Curable Cancers: Comparison of Patients with DLBCL Treated Before and During: A Retrospective Record-Based Study
por: Anandaradje, Annuja, et al.
Publicado: (2021)